Fabtech Technologies Limited has secured a major international contract worth USD 7.05 million from a West Africa-based company, as disclosed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Contract Details

The company announced on February 14, 2026, that it has bagged this significant order for the supply, installation and commissioning of infrastructure for an Oral Solid Dosage (OSD) facility. The contract value stands at USD 7,050,000.00, which translates to approximately Rs. 63.6 crores.

Project Scope and Timeline

The contract encompasses a comprehensive agreement for the supply, installation and commissioning of infrastructure required for pharmaceutical manufacturing. The project is scheduled to be completed within 23-27 months from the date of receiving the advance payment from the client.

Confidentiality and Compliance

Due to confidentiality obligations, Fabtech Technologies has not disclosed the name of the West African client. The company has confirmed that this contract does not fall within related party transactions and that neither the promoter, promoter group, nor group companies have any interest in the entity that awarded the contract.

Strategic Significance

This international order represents a significant business development for Fabtech Technologies, demonstrating the company's capabilities in pharmaceutical infrastructure projects across global markets. The contract reinforces the company's position in the international pharmaceutical equipment and infrastructure sector, particularly in emerging markets like West Africa.

Fabtech Technologies Limited conducted its Q3FY26 earnings conference call on February 10, 2026, providing comprehensive insights into the company's performance and strategic direction. The pharmaceutical engineering company addressed revenue timing challenges while maintaining confidence in its annual guidance and long-term growth trajectory.

Q3FY26 Performance and Revenue Recognition

During the earnings call, management explained that Q3FY26 softness was purely a timing issue rather than demand-related concerns. The company operates on a shipment-based revenue recognition model for its export-oriented design-build projects, which can lead to quarterly fluctuations.

The management emphasized that meaningful project execution was completed during Q3, but shipments and inspections moved into Q4. Additionally, front-loaded costs such as engineering, mobilization, and international business development were absorbed in Q3, while corresponding revenues will be recognized with a lag.

Order Book and Business Pipeline

Fabtech Technologies demonstrated strong business momentum with a robust order book position. As of January 31, 2026, the company's outstanding order book stood at Rs 926.00 crores, reflecting healthy demand for its life sciences infrastructure solutions.

FY26 Guidance and Growth Projections

Despite Q3 timing challenges, management reaffirmed its annual guidance for FY26. The company maintains its focus on yearly performance rather than quarterly fluctuations, given the nature of its project-based business model.

For FY27, the company is targeting 30% year-on-year growth, supported by increasing ticket sizes and expanding market presence across pharmaceutical emerging markets.

Strategic Positioning and Market Focus

Fabtech Technologies positions itself as India's global design-build platform for advanced life sciences infrastructure, focusing on pharmaceutical emerging markets including the Middle East, Africa, Persian Gulf, and GCC regions. The company operates as a turnkey life sciences platform with in-house process air and water manufacturing capabilities.

IPO Proceeds Utilization Update

The earnings call also referenced the company's Q3FY26 monitoring agency report for IPO proceeds utilization. From the gross proceeds of Rs 23,029.65 lakhs raised in September-October 2025, the company utilized Rs 125.00 lakhs during Q3 specifically for general corporate purposes, primarily salary and wages payments. The majority of unutilized proceeds remain strategically deployed in fixed deposits with leading banks, earning returns while preserving capital for future initiatives.

Acquisition Strategy and Future Plans

Management outlined plans for strategic acquisitions, particularly targeting European entities to strengthen conversion rates and market positioning. The company expects to complete acquisitions within the next six months, with a focus on enhancing local presence in key markets and improving win rates from the current 15% to 20-25%.

The company also indicated potential expansion into adjacent sectors such as data centers and food security infrastructure, while maintaining primary focus on the substantial pharmaceutical infrastructure opportunity in emerging markets. Management emphasized building for long-term structural growth rather than quarterly performance, positioning Fabtech Technologies as a key enabler of medicinal independence in emerging geographies.